C4 Therapeutics, Inc. (CCCC)
NASDAQ:CCCC
Want to see CCCC full AI Analyst Report?
CCCC Stock Chart & Stats
$2.92
-$0.05(-1.30%)
At close: 4:00 PM EST
$2.92
-$0.05(-1.30%)
Day’s Range― - ―
52-Week Range$1.36 - $4.60
Previous CloseN/A
Volume165.25K
Average Volume (3M)2.81M
Market Cap
$425.68M
Enterprise Value$359.13M
Total Cash (Recent Filing)$235.67M
Total Debt (Recent Filing)$58.45M
Price to Earnings (P/E)―
Beta2.37
Next Earnings
Aug 12, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.19
Shares Outstanding110,567,220
10 Day Avg. Volume2,646,424
30 Day Avg. Volume2,806,369
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.62
Price to Sales (P/S)4.40
P/FCF Ratio-1.59
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue10.30
Enterprise Value/Gross Profit10.86
Enterprise Value/Ebitda-3.32
Forecast
1Y Price Target
$10.33Price Target Upside253.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.97
Revenue Forecast (FY)$21.62M
Bulls Say, Bears Say
Bulls Say
Strategic Roche CollaborationThe expanded Roche collaboration provides non-dilutive funding, strategic validation and commercialization scale. Roche leads development, regulatory and commercialization while C4 supplies TORPEDO payloads and retains royalties, structurally de‑risking development and amplifying long‑term commercial optionality.
Pipeline Progress And Platform ValidationActive clinical advancement across multiple oncology programs and combination studies shows the TORPEDO platform is productive and de‑risking. Multiple shots on goal and upcoming data presentations create sustained scientific validation and expand future partnering or commercialization paths.
Substantial Near-term Cash RunwayA reported cash balance that management expects to fund operations into 2028 gives the company time to advance key trials and realize partnership milestones without immediate financing. This materially improves short‑to‑medium term balance sheet durability versus typical clinical‑stage peers.
Bears Say
High Cash BurnPersistent negative operating and free cash flow near ~$95M TTM signals heavy ongoing cash consumption to fund R&D. If milestone or partner receipts are delayed, the company will face financing pressure, increasing dilution or covenant risk and reducing long‑term financial flexibility.
Deep Negative ProfitabilityVery large operating and net losses, and deeply negative ROE, reflect that expenses far exceed current revenue. Structural profitability is distant absent major product approvals or meaningful recurring revenue, making cash needs and capital markets access ongoing strategic constraints.
Modest, Slightly Declining Revenue BaseA small and falling revenue base increases reliance on one‑off collaboration payments and milestones rather than durable product sales. That revenue profile raises variability in funding, making long‑term planning and margin improvement contingent on successful clinical and partnering outcomes.
C4 Therapeutics News
CCCC FAQ
What was C4 Therapeutics, Inc.’s price range in the past 12 months?
C4 Therapeutics, Inc. lowest stock price was $1.36 and its highest was $4.60 in the past 12 months.
What is C4 Therapeutics, Inc.’s market cap?
C4 Therapeutics, Inc.’s market cap is $425.68M.
When is C4 Therapeutics, Inc.’s upcoming earnings report date?
C4 Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 65 days.
How were C4 Therapeutics, Inc.’s earnings last quarter?
C4 Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.251 by $0.051.
Is C4 Therapeutics, Inc. overvalued?
According to Wall Street analysts C4 Therapeutics, Inc.’s price is currently Undervalued.
Does C4 Therapeutics, Inc. pay dividends?
C4 Therapeutics, Inc. does not currently pay dividends.
What is C4 Therapeutics, Inc.’s EPS estimate?
C4 Therapeutics, Inc.’s EPS estimate is -0.22.
How many shares outstanding does C4 Therapeutics, Inc. have?
C4 Therapeutics, Inc. has 110,567,220 shares outstanding.
What happened to C4 Therapeutics, Inc.’s price movement after its last earnings report?
C4 Therapeutics, Inc. reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.251. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of C4 Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CCCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
C4 Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.33 (253.88% Upside)
$10.33 (253.88% Upside)
Blogger Sentiment
Bullish
CCCC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 306.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 9.5%
Last 30 Days ▲ 9.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
161.90%
12-Months-Change
Fundamentals
Return on Equity
-50.68%
Trailing 12-Months
Asset Growth
2.92%
Trailing 12-Months
Company Description
C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.
CCCC Stock 12 Month Forecast
Average Price Target
$10.33
▲(253.88% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Seres Therapeutics
―
Eledon Pharmaceuticals
―
Tevogen Bio Holdings
―
Actuate Therapeutics, Inc.
―
Ownership Overview
2.97% Insiders
8.49% Mutual Funds
34.52% Other Institutional Investors
47.95% Public Companies and
Individual Investors